<DOC>
	<DOCNO>NCT02615574</DOCNO>
	<brief_summary>The investigator hypothesize treatment metastatic colorectal cancer ( mCRC ) patient combination alpha-type-1-polarized dendritic cell ( αDC1 ) vaccines tumor-selective chemokine modulation ( CKM ) promote infiltration vaccination-induced CD8+ CTLs tumor lesion subsequently tumor regression improve patient survival .</brief_summary>
	<brief_title>A Study Type-1 Polarized Dendritic Cell ( αDC1 ) Vaccine Combination With Tumor-Selective Chemokine Modulation ( Interferon-α2b , Rintatolimod , Celecoxib ) Subjects With Chemo-Refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Metastatic colorectal cancer major health concern United States , second lead cause death due cancer . The purpose trial see combination study vaccine drug patient disease prevent growth cancer prevent new tumor grow . The study drug combination celecoxib ( Celebrex® ) , Interferon-α2b ( IFN ) , rintatolimod ( Ampligen® ) , CKM .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Be age equal 18 year old . Be able understand willing sign write informed consent document . Be HLAA2 positive . Have mCRC treat currently approve standard therapy , include fluoropyrimidine , oxaliplatin irinotecanbased chemotherapy , antiVEGF therapy , , KRAS wild type , antiEGFR therapy . Have least 1 tumor site must amenable core needle biopsy may site disease use measure antitumor response . Have measurable disease base irRC . Have performance status ECOG 0 1.Have normal organ marrow function define : Platelet ≥ 75,000/µL Hemoglobin ≥ 9.0 g/dL Absolute Neutrophil Count ( ANC ) ≥ 1500/µL Creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) OR creatinine clearance ( CrCl ) ≥ 50 mL/min/1.73 m2 subject creatinine level great 1.5 x ULN Total bilirubin ≤ 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x institutional upper limit normal ( ULN ) OR ≤ 5 x ULN subject liver metastasis Serum amylase lipase within normal limit . Is currently treat systemic immunosuppressive agent , include steroid , ineligible 3 week removal immunosuppressive treatment . Has prior chemotherapy , target small molecule therapy , radiation therapy within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease history transplantation . Is woman child bear potential ( WOCBP ) pregnant nursing . Has history cardiac event ( ) ( acute coronary syndrome , myocardial infarction , ischemia ) within 3 month sign consent . Subjects New York Heart Association classification III IV . Has history upper gastrointestinal ulceration , upper gastrointestinal bleeding , upper gastrointestinal perforation within past 3 year . Subjects ulceration , bleed perforation low bowel exclude . Has prior allergic reaction hypersensitivity celecoxib , NSAIDs . Has active infection require systemic therapy . Has significant ascites pleural effusion require drainage symptom relief . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C infection . Has history asthma , allergictype reaction take aspirin NSAIDs . Has know serious hypersensitivity reaction peginterferon alfa2b interferon alfa2b . Has autoimmune hepatitis . Has hepatic decompensation ( ChildPugh score &gt; 6 ; = class B C ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>